PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study
Dragomir, R.; Sas, I.; Săftescu, S.; Popovici, D.; Margan, R.; Dragomir, A.S.; Stanca, H.; Mocanu, V.; Pac, C.; Negru, Ș. Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study. Preprints2021, 2021050391. https://doi.org/10.20944/preprints202105.0391.v1
APA Style
Dragomir, R., Sas, I., Săftescu, S., Popovici, D., Margan, R., Dragomir, A.S., Stanca, H., Mocanu, V., Pac, C., & Negru, Ș. (2021). Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study. Preprints. https://doi.org/10.20944/preprints202105.0391.v1
Chicago/Turabian Style
Dragomir, R., Cristina Pac and Șerban Negru. 2021 "Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study" Preprints. https://doi.org/10.20944/preprints202105.0391.v1
Abstract
Ovarian cancer (OC) represents the most common and lethal gynecologic malignancy, due to its increased incidence and mortality rate. It is usually diagnosed in advanced stages and, even though surgery and platinum-based treatment are initially efficient, recurrences emerge in over 70% of cases. Although there are multiple options of chemotherapy drugs from which to choose, little is known regarding the best strategy for prolonged survival. Thus, the aim of this study was to assess the effect that most frequently used chemotherapeutic regimens have upon time-to-treatment-failure (TTF) from the first line and beyond, considering clinical and biological factors which influence the treatment outcome of platinum-resistant recurrent OC. We retrospectively analyzed data from 78 patients diagnosed with platinum-resistant OC, who underwent chemotherapy-based treatment with or without anti-angiogenic therapy at OncoHelp Oncology Center, Romania (January 2016 - February 2021). Our study identified positive predictive factors for TTF related to anthropometry (age over 60 for patients treated with topotecan with or without bevacizumab), renal function (creatinine levels between 0.65 and 1 mg/dl for patients treated with regimens containing bevacizumab and pegylated liposomal doxorubicin) and treatment choice (bevacizumab in combination with pegylated liposomal doxorubicin or topotecan used from the first line and beyond).
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
